Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Cancer Discov. 2013 Jan 29;3(5):520–533. doi: 10.1158/2159-8290.CD-12-0531

Figure 7.

Figure 7

Model of HER2/HER3-induced primary resistance to MAPK inhibitors in BRAF mutant thyroid cancer cells. RAF or MEK inhibitors release transcription repressor CTBP protein/s from the HER3 promoter and induce HER3 gene expression. Autocrine-secreted NRG-1 binds to HER3, triggers HER3/HER2 heterodimerization and receptor phosphorylation, inducing PI3K and reactivating MAPK signaling, thus promoting resistance to growth inhibition.